Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments

France Nouvelles Nouvelles

Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments
France Dernières Nouvelles,France Actualités
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Coronavirus Update: Pfizer and BioNTech launch study of omicron-specific vaccine

One day after the U.S. Food and Drug Administration said it’s halting the use of antibody drugs as COVID-19 treatments because they don’t work on the highly contagious omicron variant, Pfizer and German partner BioNTech announced they are launching a trial to evaluate an omicron-oriented vaccine in healthy adults aged 18 to 55.

On Monday, the FDA said the COVID antibody drugs from Regeneron REGN, -1.85% and Eli Lilly LLY, -1.45% should no longer be used as treatments and revoked its emergency-use authorization for both drugs. In a statement, the agency acknowledged that omicron now accounts for 99% of new cases, making it “highly unlikely” they would help people seeking treatment, as the Associated Press reported.

Hospitalizations remain above 156,000 a day but seem to be reaching a peak in many places. But deaths are still above 2,000 a day, meaning the U.S. is suffering casualties on the same scale as the terrorist attacks of Sept. 11, 2001, every two days. A New York state judge ruled Monday that the state’s face-mask mandate in public places is unconstitutional and now void, the New York Times reported, citing court documents.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

MarketWatch /  🏆 3. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Pfizer, BioNTech begin omicron-specific COVID-19 vaccine studyPfizer, BioNTech begin omicron-specific COVID-19 vaccine studyCOVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
Lire la suite »

Pfizer opens study of COVID shots updated to match omicronPfizer opens study of COVID shots updated to match omicronPfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious omicron variant. Pfizer...
Lire la suite »

Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - studySinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - studyA third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found.
Lire la suite »

Pfizer starts clinical trial for omicron-specific Covid vaccinePfizer starts clinical trial for omicron-specific Covid vaccineJUST IN: Pfizer and BioNTech announce that they have started a clinical trial testing a modified Covid-19 vaccine to protect against the omicron variant.
Lire la suite »

Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Lire la suite »

Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Lire la suite »



Render Time: 2025-04-16 21:35:12